Public Release: 

Archimedes new study shows health checks may lead to cost effective improvements in health

Data published in journal PLOS ONE provides realistic estimate of likely 30-year health and cost benefits of health checks in Germany, the UK, France, Denmark, Italy, and Poland

GCI Health

San Francisco, CA, USA - Jul 15, 2013 - Archimedes Inc., a healthcare modeling company, today announced the results of a two-year long collaboration with Novo Nordisk A/S, a world leader in diabetes care, which evaluated the effects of standardized vascular health checks on expected health outcomes. The study, "A Standardized Vascular Disease Health Check in Europe: A Cost-Effectiveness Analysis," appearing in the July 15th issue of the peer-reviewed online journal PLOS ONE, showed that health check strategies assessing diabetes, hypertension, lipids and smoking over a 30-year period would likely improve health and cost-effectiveness outcomes in six European countries, including Germany, the United Kingdom (UK), France, Denmark, Italy, and Poland.

"This study using the Archimedes Model shows that offering health checks would likely reduce the 30-year incidence of major cardiovascular events including heart attack, stroke or death, and serious complications such as diabetes-related blindness and chronic kidney disease," said study author Ulf Smith, MD, PhD, Sahlgrenska University Hospital in Gothenburg, Sweden. "Based on this study, pre-screening strategies for treating common conditions that are increasingly becoming of concern across Europe could reduce the total budget impact of launching a health check program while leading to meaningful improvements in health."

The health check, a multi-faceted preventative intervention, was modeled after a program designed by the United Kingdom National Health Service. Using the Archimedes Model, researchers simulated a clinical trial comparing seven health check strategies to current levels of care using a simulated population of patients that matched the demographic characteristics and other risk factors in Germany, the UK, France, Denmark, Italy, and Poland.

"This study marks an exciting step forward in Archimedes' mission to improve the quality and efficiency of healthcare worldwide," said Andy Schuetz, Ph.D., Archimedes' director of population products and lead author of the manuscript. "In this work, we leveraged our capability to realistically model European populations and healthcare systems. While this study was in-press, we've also modeled Russian and Japanese settings and we are using these capabilities to inform decision makers around the globe about opportunities to improve care."


Additional background about the study and the full publication is available here.


Archimedes Inc. is a healthcare modeling organization. Its core technology - the Archimedes Model - is a clinically realistic, mathematical model of human physiology, diseases, interventions and healthcare systems. Archimedes continually validates the Model by comparing the results of simulated trials to the results of multi-national clinical trials and cohort studies. Through products such as IndiGO and ARCHeS, Archimedes works to help people understand the implications of their decisions. For the last 15 years, Archimedes has assisted health plans, health systems, medical groups, patients, pharmaceutical companies, researchers, and other organizations in the United States and Europe answer questions related to health and economic outcomes research, policy creation, clinical trial design, and performance improvement. Archimedes, a Kaiser Permanente Innovation, is based in San Francisco, California. For more information about Archimedes and its product offerings, please visit the company's web site at

Edie DeVine
GCI Health for Archimedes

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.